An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease
Author:
Open Access
- 1 May 2012
- journal article
- review article
- Published by Taylor & Francis in Core Evidence
- Vol. 7, 15-20
Abstract
Peer reviewed article authored by (Hollak CE). Read article or submit your manuscript for publishing.Keywords
This publication has 14 references indexed in Scilit:
- Pivotal trial with plant cell–expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher diseaseBlood, 2011
- 'Pharmers' hope for first plant drug harvestNature Reviews Drug Discovery, 2011
- Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experienceBlood, 2010
- Characterization of gene-activated human acid- -glucosidase: Crystal structure, glycan composition, and internalization into macrophagesGlycobiology, 2009
- A Plant-Derived Recombinant Human Glucocerebrosidase Enzyme—A Preclinical and Phase I InvestigationPLOS ONE, 2009
- Recommendations for the management of the haematological and onco‐haematological aspects of Gaucher disease1British Journal of Haematology, 2007
- Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell systemPlant Biotechnology Journal, 2007
- Quantification of Skeletal Involvement in Adults with Type I Gaucher's Disease: Fat Fraction Measured by Dixon Quantitative Chemical Shift Imaging as a Valid ParameterAmerican Journal of Roentgenology, 2002
- Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.Journal of Clinical Investigation, 1994
- Replacement Therapy for Inherited Enzyme Deficiency — Macrophage-Targeted Glucocerebrosidase for Gaucher's DiseaseNew England Journal of Medicine, 1991